Metraipolis › archive › dc_2270629492ce

FDA orphan products clinical trial grants: assessment of outcomes and impact on rare disease product development — Europe PMC PMID:32883327

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/32883327
DOI
10.1186/s13023-[numero omesso]-5
License (as archived)
solo-consultazione
Archived
2026-10-08T03:22:44.750Z
SHA-256 of the archived text
0ad8f4e2f9f8abc863fed3a23cd188b4464a789742bb1e3c9722efe72c8124d5
Stable URL of this page
https://metraipolis.com/documento/dc_2270629492ce

How to cite

FDA orphan products clinical trial grants: assessment of outcomes and impact on rare disease product development — Europe PMC PMID:32883327 — Europe PMC (en), https://europepmc.org/article/MED/32883327 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_2270629492ce (Metraipolis archive dc_2270629492ce, sha256 0ad8f4e2f9f8abc863fed3a23cd188b4464a789742bb1e3c9722efe72c8124d5)
BibTeX
@misc{dc2270629492ce,
  title = {FDA orphan products clinical trial grants: assessment of outcomes and impact on rare disease product development — Europe PMC PMID:32883327},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/32883327},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_2270629492ce; sha256 0ad8f4e2f9f8abc863fed3a23cd188b4464a789742bb1e3c9722efe72c8124d5},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/32883327. Agents can read the archived copy with the MCP tool read_document.